These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23617953)

  • 41. Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience.
    Birkmayer W; Birkmayer GD
    J Neural Transm Suppl; 1986; 22():219-25. PubMed ID: 3097256
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Abou-Taleb BA; Megallaa MH; Khalafallah NM; Khalil SH
    Drug Dev Ind Pharm; 2020 Feb; 46(2):192-199. PubMed ID: 31937146
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial.
    Pakkenberg H; Birket-Smith E; Dupont E; Hansen E; Mikkelsen B; Presthus J; Rautakorpi I; Riman E; Rinne UK
    Acta Neurol Scand; 1976 May; 53(5):376-85. PubMed ID: 1266576
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quality Testing of Difficult-to-Make Prescription Pharmaceutical Products Marketed in the US.
    Fisher AC; Viehmann A; Ashtiani M; Friedman RL; Buhse L; Kopcha M; Woodcock J
    JAMA Netw Open; 2020 Aug; 3(8):e2013920. PubMed ID: 32833019
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: A controlled clinical trial.
    Rinne UK; Birket-Smith E; Dupont E; Hansen E; Hyyppä M; Marttila R; Mikkelsen B; Pakkenberg H; Presthus J
    J Neurol; 1975 Dec; 211(1):1-9. PubMed ID: 56427
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease.
    Steiger MJ; Stocchi F; Bramante L; Ruggieri S; Quinn NP
    Clin Neuropharmacol; 1992 Dec; 15(6):501-4. PubMed ID: 1477849
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interchangeability between paracetamol tablets marketed in Palestine. Is there a quality reason for a higher price?
    Zaid A; Rinno T; Jaradat N; Jodeh S; Khammash S
    East Mediterr Health J; 2013 Jun; 19(6):542-6. PubMed ID: 24975183
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A controlled release form of madopar in parkinsonian patients with advanced disease and marked fluctuations in motor performance.
    Jensen NO; Dupont E; Hansen E; Mikkelsen B; Mikkelsen BO
    Acta Neurol Scand; 1988 May; 77(5):422-5. PubMed ID: 3046226
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Efficiency of new forms of madopar in Parkinson's disease].
    Vendrova MI; Sadekov RA; Golubev VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(12):46-8. PubMed ID: 11195538
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
    Limousin P; Pollak P; Pfefen JP; Tournier-Gervason CL; Dubuis R; Perret JE
    Clin Neuropharmacol; 1995 Jun; 18(3):258-65. PubMed ID: 8635184
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fifty cases of Parkinson's disease treated by acupuncture combined with madopar.
    Ren XM
    J Tradit Chin Med; 2008 Dec; 28(4):255-7. PubMed ID: 19226892
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Levodopa/benserazide ('Madopar') combination therapy in elderly patients with parkinsonism.
    Williams BO; Carlyle D
    Curr Med Res Opin; 1979; 6(1):1-7. PubMed ID: 378553
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Open clinical study of Madopar HBS.
    Ludin HP
    Eur Neurol; 1987; 27 Suppl 1():73-5. PubMed ID: 3322838
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study.
    Desai RJ; Sarpatwari A; Dejene S; Khan NF; Lii J; Rogers JR; Dutcher SK; Raofi S; Bohn J; Connolly J; Fischer MA; Kesselheim AS; Gagne JJ
    BMJ; 2018 Apr; 361():k1180. PubMed ID: 29615391
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Madopar HBS. International workshop on the 'on-off-phenomenon in Parkinson's disease. New possibilities for its management. Agno, November 14-16, 1985.
    Eur Neurol; 1987; 27 Suppl 1():1-142. PubMed ID: 3428304
    [No Abstract]   [Full Text] [Related]  

  • 56. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
    Fernández Pardal MM; Gatto E; Micheli F; Casas Parera I; Diaz S
    Medicina (B Aires); 1991; 51(6):561-7. PubMed ID: 7476112
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa).
    Zhang TT; Song M; Hang TJ; Xu XF; Wen AD; Yang L; Jia L
    J Clin Pharm Ther; 2009 Jun; 34(3):345-54. PubMed ID: 19646081
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.
    Birkmayer W; Riederer P; Ambrozi L; Youdim MB
    Lancet; 1977 Feb; 1(8009):439-43. PubMed ID: 65560
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK; Rinne JO
    Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of pharmaceutical quality of eight generic ganciclovir injections in China and Cymevene.
    Hong C; Wang J
    J Chemother; 2018 Sep; 30(5):310-315. PubMed ID: 30843773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.